Science and Technology Partnerships

科技合作伙伴

• 批准号: 7593004
• 负责人: David Goldstein
• 金额: $ 616.3万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7593004
• 关键词: Address; Affinity; Agreement; Antibodies; Area; Binding; Bioinformatics; Biological; Biomedical Computing; Biometry; Biotechnology; CCR; Clinical Research; Collaborations; Communities; Complex; Computer software; Contracts; Cost Savings; Data; Data Sources; Databases; Development; Educational workshop; Environment; Funding; Funding Mechanisms; Future; Genetic; Genetic Screening; Genomics; Hepatocarcinogenesis; Imagery; Individual; Internet; Investigation; Journals; Knowledge; Laboratories; Licensing; Malignant Neoplasms; Malignant neoplasm of ovary; Marketing; Mediation; Methodology; Microarray Analysis; Molecular; Monoclonal Antibodies; Neoplasm Metastasis; Neuroblastoma; Numbers; Pathway Analysis; Pathway interactions; Phosphorylation Site; Price; Principal Investigator; Private Sector; Process; Proteins; Proteomics; Publications; Radiation Oncology; Range; Reagent; Research; Research Personnel; Resources; Savings; Science; Scientist; Screening procedure; Services; Signal Pathway; Signal Transduction; Site; Software Tools; Support of Research; System; Technology; Technology Transfer; Training and Education; Transfer Agreement; Yeasts; anticancer research; base; cancer type; commercialization; cost; design; interest; neuro-oncology; next generation; novel; payment; programs; protein protein interaction; repository; research study; response; software development; symposium; tool; yeast two hybrid system

Development of Novel Affinity Reagents: During the past fiscal year, the OSTP has continued to support an initiative for generating high affinity reagents to serve as tools for molecular interrogation of pathways that become altered during cancer development. Partnerships with two biotechnology companies, Beckton Dickinson Pharmingen and Rockland Immunochemicals have led to the creation of nearly 200 novel affinity reagents (polyclonal and monoclonal antibodies) against hundreds of key cancer-related targets of interest to CCR at no cost to the CCR investigators. These partnerships represent savings of over one million dollars to CCR and the NCI. The antibodies that have been developed through these partnerships includes: (1) novel candidate proteins for which no commercially available antibodies exist; (2) known proteins for which commercially available antibodies exist but fail to meet investigators' requirements; and (3) proteins with phosphorylation sites that may be of importance in pathways that are altered during cancer development. All of the antibody characterization data generated by participating CCR investigators is made available to the companies through a web site developed in collaboration between the OSTP and the Advanced Biomedical Computing Center (ABCC). The company uses the data in their marketing material when the antibodies are released for commercialization. Discovery of Novel Protein-Protein Interactions: The OSTP supported a number of programs for defining novel cancer relevant protein-protein interactions and cell signaling networks. For example, OSTP has been managing a major screening program to identify and characterize novel binding partners to a large number of cancer-related proteins currently under investigation within the CCR. A CCR-wide partnership with Myriad Genetics was developed to access their automated process for the large-scale identification of protein-protein interactions that is based on the Yeast Two-Hybrid (Y2H) methodology. This large-scale effort between CCR and Myriad has already generated a host of data (over 1,600 novel protein interactions have been transferred to CCR PI's to date) that are permitting the delineation of previously uncharacterized signaling pathways and a better understanding of the molecular basis underlying cancer. The data derived from these screens has been made available to CCR investigators through a web site developed in collaboration between OSTP and the ABCC. Facilitating Access to Genomic Technologies: The OSTP has been evaluating all commercially available platforms for microarray and other high throughput genomic technologies. To make the latest advances easily accessible to CCR researchers, the OSTP has established a number of contracts and pricing arrangements with companies providing genomic profiling technologies and services (Affymetrix, NimbleGen, Agilent, Illumina, GenUs, SuperArray, etc). These agreements have led to far lower cost and an efficient and easy way for CCR investigators to access these technologies. A subsidy program has been established providing 50% payment to the CCR community for all microarrays that are purchased from these companies or full-service microarray analysis that is requested. This funding mechanism has helped to extend the limited research dollars available to CCR laboratories and has permitted our researchers to conduct experiments that might otherwise be cost prohibitive. Many of the funded projects have led to important publications in top tier journals. Most recently, the OSTP has been coordinating CCRs efforts to access the ultra high throughput, next generation sequencing technologies. OSTP was involved in all aspects of acquisition of two Illumina/Solexa Genetic Analyzers that will be installed in two CCR laboratories. The OSTP will be providing investigators subsidy funds to make this very expensive technology accessible to many CCR labs. Tools for Bioinformatics and Biostatistics Analysis: In response to CCRs rapidly growing need to manage and analyze large sets of genomic and proteomic data, the OSTP has developed several partnerships with bioinformatics companies. At significant cost savings to NCI, OSTP negotiated a variety of license agreements on behalf of all NCI researchers for universal access to sophisticated tools for bioinformatic and statistical analysis of microarray experiments, arrayCGH studies, proteomic profiling studies, genomic analysis, and genetic screens. In addition, the OSTP has made a number of software applications for the investigation of pathways and biological association networks available to all of NCI. A CCR/NCI Integrated and Collaborative Knowledge Environment: To address the complexities associated with querying across the growing number and ever-expanding public and private databases, the OSTP has established a new program to develop a CCR/NCI integrated and collaborative knowledge environment in collaboration with Sophic Systems Alliance and Biomax. Software developed by Biomax enables the visualization of complex relationships between biological and biomedical data and information. It is designed to institutionalize knowledge by enabling the annotation of information stored in a central repository. The Knowledge Environment was configured to support research on different types of cancer, sources of data, and research strategies. The CCR/NCI laboratories are configuring the Biomax software according to their individual research requirements to determine its benefits to cancer research at CCR. The areas of research include ovarian cancer, metastasis, liver carcinogenesis, neuroblastoma, radiation oncology, and neuro-oncology. Each lab requires configuration of their software instance that is tailored to the type of research conducted in that lab. The Common CCR Knowledge Environment was configured to provide access to 35 public databases integrated into a single user interface, allowing scientists to query a wide range of data sources. Information derived through genomics, proteomics, pathway analysis, and clinical studies are combined into graphical representations of complex relationships. Future plans for the Common CCR Knowledge Environment include the integration of additional databases, genomic and proteomic analysis tools, and software

新型亲和力试剂的开发：在过去的财政年度中，OSTP继续支持一项倡议，以产生高亲和力试剂，以作为在癌症发展过程中改变途径的分子询问的工具。 与两家生物技术公司，贝克顿·迪金森·普药（Beckton Dickinson Pharmingen）和罗克兰免疫化学物质的合作关系导致了针对数百种与CCR CCR调查员无关的癌症相关癌症关注的关键目标的关键关联目标，从而创建了近200个新颖的亲和力试剂（多克隆和单克隆抗体）。这些合作伙伴关系代表了CCR和NCI的一百万美元。通过这些伙伴关系开发的抗体包括：（1）新的候选蛋白质不存在市售抗体； （2）存在商业可用抗体但无法满足调查人员要求的已知蛋白质； （3）具有磷酸化位点的蛋白质在癌症发育过程中发生改变的途径中可能很重要的蛋白质。参与CCR研究人员生成的所有抗体表征数据均通过OSTP与高级生物医学计算中心（ABCC）合作开发的网站提供给公司。释放抗体进行商业化时，该公司使用其营销材料中的数据。新型蛋白质蛋白质相互作用的发现：OSTP支持许多定义新型癌症相关蛋白质蛋白质相互作用和细胞信号网络的程序。例如，OSTP一直在管理一个主要的筛查程序，以识别和表征与目前正在研究CCR中正在研究的大量癌症相关蛋白质的新型结合伙伴。开发了与无数遗传学的CCR范围合作伙伴关系，以访问其自动化过程，以大规模鉴定基于酵母双杂交（Y2H）方法的蛋白质 - 蛋白质相互作用。 CCR和Myriad之间的这种大规模努力已经产生了大量数据（迄今已将超过1,600种新型蛋白质相互作用转移到CCR PI），这允许划定以前未经表征的信号通路，并更好地了解分子基础癌症的分子基础。通过OSTP与ABCC之间的协作，通过与CCR研究人员一起提供了从这些屏幕中得出的数据。促进获得基因组技术的访问：OSTP一直在评估微阵列和其他高吞吐量基因组技术的所有市售平台。为了使CCR研究人员容易获得最新进展，OSTP与提供基因组分析技术和服务的公司（Affymetrix，Nimblegen，Agilent，Illumina，Illumina，Genus，SuperArray等）建立了许多合同和定价安排）。这些协议导致了CCR调查人员访问这些技术的高效，简便的方法。已经建立了一项补贴计划，为从这些公司购买的所有微阵列或要求的全方位服务微阵列分析提供了50％的付款。这种资金机制有助于扩大CCR实验室可用的有限的研究资金，并允许我们的研究人员进行实验，否则可能是成本高昂的。许多资助的项目导致了顶级期刊的重要出版物。最近，OSTP一直在协调CCRS访问超高通量，下一代测序技术的努力。 OSTP参与了两个Illumina/Solexa遗传分析仪的获取的各个方面，这些遗传分析仪将安装在两个CCR实验室中。 OSTP将为调查人员提供补贴资金，以使这项非常昂贵的技术可用于许多CCR实验室。生物信息学和生物统计学分析的工具：响应CCR迅速增长的需求，以管理和分析大量基因组和蛋白质组学数据，OSTP与生物信息学公司建立了多种合作伙伴关系。 OSTP以大量的成本节省了NCI，代表所有NCI研究人员谈判了各种许可协议，以普遍访问微阵列实验的生物信息学和统计分析，用于微阵列实验，ARRAYCGH研究，蛋白质分析研究，蛋白质组织研究，基因组分析和遗传筛选。此外，OSTP为所有NCI提供的途径和生物协会网络进行了许多软件应用程序。 CCR/NCI集成和协作知识环境：解决与不断增长的公共和私人数据库查询相关的复杂性，OSTP已建立了一个新程序，以与Sophic Systems Alliance Alliance Alliance and Biomax和Biomax一起开发CCR/NCI集成和协作知识环境。 BioMax开发的软件可以可视化生物学和生物医学数据和信息之间的复杂关系。它旨在通过启用中央存储库中存储的信息的注释来制度化知识。知识环境的配置为支持对不同类型的癌症，数据源和研究策略的研究。 CCR/NCI实验室正在根据其个人研究要求配置Biomax软件，以确定其对CCR癌症研究的好处。研究领域包括卵巢癌，转移，肝癌发生，神经母细胞瘤，放射肿瘤学和神经肿瘤学。每个实验室都需要对其软件实例进行配置，该实例是针对该实验室进行的研究类型量身定制的。共同的CCR知识环境配置为可以访问35个集成到单个用户界面中的公共数据库，从而使科学家可以查询广泛的数据源。通过基因组学，蛋白质组学，途径分析和临床研究得出的信息被合并为复杂关系的图形表示。共同CCR知识环境的未来计划包括集成其他数据库，基因组和蛋白质组学分析工具以及软件